TrialBreast cancer research and treatment2024

A randomized phase III double-blind placebo-controlled trial of first-line chemotherapy and trastuzumab with or without bevacizumab for patients with HER2/neu-positive metastatic breast cancer: a trial of the ECOG-ACRIN Cancer Research Group (E1105).

Jessica Mezzanotte-Sharpe et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.